The cost of Soliris can vary based on several factors, including your insurance coverage. Drug savings programs can also lower the price you’ll pay for Soliris. Soliris may need to be purchased ...

Soliris (eculizumab) is a prescription drug used to treat certain rare autoimmune conditions. Soliris can cause side effects that range from mild to serious. Examples include headache and back pain.

In its push to backstop sales of blockbuster Soliris, Alexion has touted its better-than-expected success at switching patients to follow-up drug Ultomiris. But if switching to the newer med is going ...

It took longer than some industry watchers expected, but Alexion has another indication for lead med Soliris in the bag. On Monday, the company said the FDA had greenlighted the product to treat ...

- 98% of adult anti-aquaporin-4 (AQP4) antibody-positive patients treated with SOLIRIS were relapse free compared to 63% receiving placebo at 48 weeks - “We are pleased that the Japanese health ...

Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH - First therapy approved in both Europe and the United States for rare and life-threatening blood disease ...

Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), was observed by investigators to reduce blood measures associated with undiagnosed ...

The FDA approved a fourth indication for Alexion Pharmaceuticals’ brand-name eculizumab (Soliris) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are ...

Update: On September 29, 2021, Canada applied to the Supreme Court of Canada for leave to appeal (Docket No. 39858). According to the Board’s Guidelines, as a breakthrough drug, the highest price at ...

AstraZeneca, a global, science-led biopharmaceutical company, has made available its treatment, Soliris®, in Malaysia as part of its ongoing ...

In September 2017, the Patented Medicine Prices Review Board (PMPRB) decided that Alexion’s SOLIRIS (eculizumab) was sold at an excessive price. In doing so, the Board departed from the Guidelines, in ...

Alexion Pharmaceuticals, Inc.ALXN announced that Soliris has failed to meet the primary endpoint in a randomized, parallel-group, double-blind, placebo-controlled, multi-center phase II/III study ...